1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Zai Lab Limited
  6. Summary
    ZLAB   US98887Q1040

ZAI LAB LIMITED

(ZLAB)
  Report
Real-time Estimate Cboe BZX  -  09:34 2022-08-08 am EDT
50.53 USD   +11.62%
08/03Zai Lab Names Operations Chief
MT
08/03ZAI LAB LTD : Change in Directors or Principal Officers (form 8-K)
AQ
08/03Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/01/2022 08/02/2022 08/03/2022 08/04/2022 08/05/2022 Date
38.88(c) 38.45(c) 37.77(c) 40.83(c) 45.27(c) Last
264 529 403 163 363 339 404 940 391 904 Volume
-4.07% -1.11% -1.77% +8.10% +10.87% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 224 M - -
Net income 2022 -441 M - -
Net cash position 2022 828 M - -
P/E ratio 2022 -9,96x
Yield 2022 -
Sales 2023 393 M - -
Net income 2023 -380 M - -
Net cash position 2023 1 387 M - -
P/E ratio 2023 -10,0x
Yield 2023 -
Capitalization 4 431 M 4 431 M -
EV / Sales 2022 16,1x
EV / Sales 2023 7,74x
Nbr of Employees 1 951
Free-Float 99,8%
More Financials
Company
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical... 
Sector
Pharmaceuticals
Calendar
08/09Earnings Release
More about the company
Ratings of Zai Lab Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ZAI LAB LIMITED
08/03Zai Lab Names Operations Chief
MT
08/03ZAI LAB LTD : Change in Directors or Principal Officers (form 8-K)
AQ
08/03Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer
CI
07/27SEC Chair Stresses Need to Reach Audit Deal With Chinese Regulators
MT
07/26China’s Securities Watchdog Denies Plan to Help Firms Avoid US Delisting
MT
07/20Deal to Avoid Delisting of 200 Firms in US Bourses Remains Unclear
MT
07/19Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022
GL
07/18SECTOR UPDATE : Health Care Stocks Extending Monday Slide
MT
07/18Zai Lab Rises After Joining Two Stock Connect Programs
MT
07/18SECTOR UPDATE : Health Care Stocks Sinking in Monday Trading
MT
07/17Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs
GL
07/17Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs
AQ
07/13Zai Lab Says China Granted its BLA Clearance for Efgartigimod for Patients With General..
MT
07/13Zai Lab Announces Acceptance by China's NMPA of the BLA for Efgartigimod for Patients w..
GL
07/13China’s National Medical Products Administration Accepts Biologics License Applica..
CI
More news
News in other languages on ZAI LAB LIMITED
08/03Zai Lab Limited nomme Joshua Smiley au poste de directeur de l'exploitation
07/28Tweede kwartaal Argen-x in teken lancering Vyvgart
07/18MISE À JOUR SECTORIELLE : Les actions du secteur de la santé prolongent la baisse de lundi
07/18Zai Lab s'élève après avoir rejoint deux programmes Stock Connect
07/18MISE À JOUR SECTORIELLE : Les actions du secteur de la santé en baisse lundi soir
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 45,27 $
Average target price 101,05 $
Spread / Average Target 123%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Joshua L. Smiley Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-27.97%4 431
CSL LIMITED2.07%98 543
SAMSUNG BIOLOGICS CO.,LTD.-0.89%48 860
WUXI BIOLOGICS (CAYMAN) INC.-19.88%40 273
BIOGEN INC.-9.05%31 664
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-19.97%23 596